Gutierrez-Gutierrez, BelenBonomo, Robert ACarmeli, YehudaPaterson, David LPascual, AlvaroRodriguez-Baño, Jesus2023-01-252023-01-252017Gutiérrez-Gutiérrez B, Bonomo RA, Carmeli Y, Paterson DL, Pascual A, Rodríguez-Baño J. Combination therapy for bloodstream infections with carbapenemase-producing Enterobacteriaceae - Authors' reply. Lancet Infect Dis. 2017 Oct;17(10):1020-1021.http://hdl.handle.net/10668/11609We thank Bernd Salzberger and Gerd Fätkenheuer for their interest in our study.1 They were concerned about the use of Charlson, Pitt, and INCREMENT-CPE scores, as well as the individual variables contained in them in the analyses. Our objective was to provide the best possible estimation of the association of the main exposure ( treatment ) with the outcome considering the effect of confounders, in accordance with the study hypothesis; we did not intend to provide a model to predict outcome ( mortality ). Therefore, we did several multivariate analyses , including models with the individual variables, models with the scores, and models with both, after checking for collinearity. The best models were selected and are shown in tables 2 and 3 of our paper .1 As a result, when the scores were considered, the individual variables were not relevant and the effect of treatment on mortality was adjusted by the scores.enAnti-Bacterial AgentsBacterial ProteinsEnterobacteriaceaeHumansbeta-LactamasesBacteremiaCarbapenem-Resistant EnterobacteriaceaeEnterobacteriaceae InfectionsMicrobial Sensitivity Testsletter28948921Restricted AccessMortalidadTerapéuticaAnálisis multivariantePapelReflujo gastroesofágicoAsociación10.1016/S1473-3099(17)30522-41474-4457http://www.thelancet.com/article/S1473309917305224/pdf